NEW YORK – 10x Genomics said after market close on Thursday that it has entered a definitive agreement to acquire single-cell biology company Scale Biosciences for upfront cash

纽约——10x Genomics在周四收盘后表示，已达成最终协议，将以现金收购单细胞生物学公司Scale Biosciences。

and stock consideration of $30 million, plus contingent consideration that could become payable upon the achievement of certain milestones.

以及3000万美元的股票对价，加上在实现某些里程碑时可能支付的或有对价。

10x said the acquisition will provide the company with 'key inventions and technologies' that will advance its Chromium single-cell platform as well as support the company's 'ambitious multi-year product roadmap' for single-cell biology.

10x表示，此次收购将为公司提供“关键的发明和技术”，这将推动其Chromium单细胞平台的发展，并支持公司在单细胞生物学领域“雄心勃勃的多年产品路线图”。

During the acquisition process, 10x said it will support current Scale Bio customers with ongoing experiments, as well as initiatives such as the 100 Million Cell Challenge and the

在收购过程中，10x 表示将支持当前 Scale Bio 客户正在进行的实验，以及诸如“一亿细胞挑战”等举措和

Billion Cells Project

亿万个细胞项目

. In addition, key products from Scale Bio will remain on the market, 10x noted.

此外，10x指出，Scale Bio的关键产品将继续留在市场上。

After the acquisition, all of Scale Bio's scientific founders — including Garry Nolan at Stanford University, Jay Shendure and Cole Trapnell at University of Washington, as well as Frank Steemers — will join 10x as advisors.

收购完成后，Scale Bio的所有科学创始人——包括斯坦福大学的加里·诺兰、华盛顿大学的杰伊·申杜尔和科尔·特拉普内尔，以及弗兰克·斯蒂默斯——都将作为顾问加入10x。

10x also announced its second quarter financial results on Thursday afternoon after market close. For the three months ended June 30, 10x booked $172.9 million in total revenues compared to $153.1 million in the prior-year period. Excluding $27.3 million related to the

10x还在周四下午收盘后公布了其第二季度的财务业绩。截至6月30日的三个月内，10x的总收入为1.729亿美元，而去年同期为1.531亿美元。排除与之相关的2,730万美元后，

patent litigation settlement

专利诉讼和解

with Bruker, 10x's Q2 core revenues were $145.6 million, down 5 percent from $153.1 million in the prior-year period. Wall Street analysts, on average, estimated revenues of $139.51 million.

与布鲁克合作，10x的第二季度核心收入为1.456亿美元，较上年同季的1.531亿美元下降了5%。华尔街分析师平均估计营收为1.3951亿美元。

Q2 instrument revenues were $14.5 million, down 39 percent from $23.9 million a year ago, while consumables revenues were $122.2 million, representing a 1 percent dip from $123.4 million in the year-ago period.

第二季度仪器收入为1450万美元，较一年前的2390万美元下降了39%，而耗材收入为1.222亿美元，较去年同期的1.234亿美元下降了1%。

Q2 Spatial instrument revenues were $8.8 million, dropping 42 percent from $15.1 in Q2 2024. The company reported $36.4 million in spatial consumables revenues, up 34 percent from $29.3 million a year ago.

第二季度空间仪器收入为 880 万美元，较 2024 年第二季度的 1510 万美元下降了 42%。公司报告称，空间耗材收入为 3640 万美元，较去年的 2930 万美元增长了 34%。

10x booked $5.7 million in Chromium instrument revenues in Q2, down 35 percent year over year from $8.8 million. Meanwhile, Chromium consumables revenues were $85.8 million, representing a 9 percent decline from $94.1 million in Q2 2024.

10x公司在第二季度录得570万美元的Chromium仪器收入，同比下降35%，去年同期为880万美元。同时，Chromium耗材收入为8580万美元，较2024年第二季度的9410万美元下降了9%。

Service revenues were $8.5 million for the quarter, up 44 percent from $5.8 million a year ago.

本季度服务收入为 850 万美元，比一年前的 580 万美元增长了 44%。

By geography, revenues from the Americas totaled $106.2 million, up 14 percent from $93.1 million a year ago. Revenues from Europe, the Middle East, and Africa totaled $34.7 million, down 7 percent from $37.4 million a year ago. Revenues from the Asia-Pacific region were $32.0 million, up 41 percent from $22.7 million in Q2 2024..

按地域划分，美洲地区的收入总计为 1.062 亿美元，比一年前的 9,310 万美元增长了 14%。欧洲、中东和非洲的收入总计为 3,470 万美元，比一年前的 3,740 万美元下降了 7%。亚太地区的收入为 3,200 万美元，比 2024 年第二季度的 2,270 万美元增长了 41%。

The firm's net income for the quarter was $34.5 million, or $.28 per share, compared to a loss of $37.9 million, or $.32 per share, in Q2 2024.

公司本季度的净收入为 3450 万美元，即每股 0.28 美元，而 2024 年第二季度的净亏损为 3790 万美元，即每股 0.32 美元。

10x's R&D expenses were $61.2 million, down 3 percent from $62.9 million a year ago. Its SG&A expenses fell 10 percent to $74.4 million from $83.0 million in Q2 2024.

10x的研发费用为6120万美元，较一年前的6290万美元下降了3%。其销售、管理及行政（SG&A）费用同比下降10%，从2024年第二季度的8300万美元降至7440万美元。

As of June 30, 10x had $397.7 million in cash and cash equivalents and $49.5 million in marketable securities.

截至6月30日，10x拥有3.977亿美元的现金及现金等价物和4950万美元的可出售证券。

10x Genomics expects third quarter revenues to be in the range of $140 million to $144 million. This guidance reflects roughly $4.0 million of revenues that resulted from 'customers in China accelerating purchases from the third quarter into the second quarter in anticipation of potential tariff changes,' the company said.

10x Genomics预计第三季度收入将在1.4亿美元至1.44亿美元之间。该公司表示，这一指导反映了“由于中国客户预期可能的关税变化，将第三季度的采购提前至第二季度”所带来的约400万美元收入。

.

。